Spyre Therapeutics Inc.
XNAS:SYRE 4:00:00 PM EDT
| Market Cap (Intraday) | 1.74B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $23.14 |
| 50-Day MA | $18.89 |
| 200-Day MA | $17.45 |
Spyre Therapeutics Inc. Stock, XNAS:SYRE
Building 17, 221 Crescent Street, Waltham, Massachusetts 02453
United States of America
Phone: +1.617.651.5940
Number of Employees: 65
Description
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.